Market capitalization | $1.07b |
Enterprise Value | $504.04m |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.21 |
Free Cash Flow (TTM) Free Cash Flow | $-169.86m |
Cash position | $564.82m |
P/E forward | negative |
Short interest | 25.72% |
As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.
10 Analysts have issued a Aeglea BioTherapeutics Inc forecast:
10 Analysts have issued a Aeglea BioTherapeutics Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -209 -209 |
16%
16%
|
EBIT (Operating Income) EBIT | -209 -209 |
16%
16%
|
Net Profit | -208 -208 |
39%
39%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
Head office | United States |
CEO | Cameron Turtle |
Employees | 65 |
Founded | 2013 |
Website | spyre.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.